CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital Adjustment	Additional Paid-in Capital	Accumulated Deficit Adjustment	Accumulated Deficit	Adjustment	Total
Beginning balance at Dec. 31, 2021	$ 46		$ 368,852		$ (374,934)		$ (6,036)
Beginning balance (in shares) at Dec. 31, 2021	45,556,647
Issuance of common stock under the Sales Agreement, net	$ 7		8,229				8,236
Issuance of common stock under the Sales Agreement, net (in shares)	7,473,038
Share-based compensation related to stock options			1,124				1,124
Share-based compensation related to restricted stock awards	$ 1		960				961
Share-based compensation related to restricted stock awards (in shares)	759,482
Exercise of warrants			2				2
Exercise of warrants (in shares)	1,000
Net income (loss)					(14,927)		(14,927)
Ending balance at Dec. 31, 2022	$ 54		379,167		(389,861)		(10,640)
Ending balance (in shares) at Dec. 31, 2022	53,790,167
Issuance of common stock under the Sales Agreement, net	$ 13		23,941				23,954
Issuance of common stock under the Sales Agreement, net (in shares)	12,560,150
Convertible notes conversions	$ 5		7,778				7,783
Convertible notes conversions (in shares)	4,691,623
Share-based compensation related to stock options			1,928				1,928
Share-based compensation related to restricted stock awards	$ 1		1,519				1,520
Share-based compensation related to restricted stock awards (in shares)	1,371,362
Exercise of warrants			712				712
Exercise of warrants (in shares)	538,822
Net income (loss)					8,312		8,312
Ending balance (ASU 2020-06) at Dec. 31, 2023		$ (393)		$ 224		$ (169)
Ending balance at Dec. 31, 2023	$ 73		415,045		(381,549)		$ 33,569
Ending balance (in shares) at Dec. 31, 2023	72,952,124						72,952,124
Issuance of common stock under the Sales Agreement, net	$ 2		3,624				$ 3,626
Issuance of common stock under the Sales Agreement, net (in shares)	2,216,692
Share-based compensation related to stock options			1,593				1,593
Share-based compensation related to restricted stock awards	$ 1		1,659				1,660
Share-based compensation related to restricted stock awards (in shares)	681,459
Net income (loss)					2,932		2,932
Ending balance at Dec. 31, 2024	$ 76		$ 421,528		$ (378,393)		$ 43,211
Ending balance (in shares) at Dec. 31, 2024	75,850,275						75,850,275